Sernova Corp. | Finanzwire

Basculer en Français

9475	Companies
185452	Keywords
117793	Articles
99303	Press releases

Home
Companies
Sernova Corp.

BRIEF

published on 06/02/2025 at 13:44, 6 months 2 days ago

Sernova Biotherapeutics Sees Potential in T1D Trial Results

Clinical Trials Investment Type 1 Diabetes Cell Pouch Sernova Biotherapeutics
PRESS RELEASE

published on 06/02/2025 at 13:39, 6 months 2 days ago

Original-Research: Sernova Biotherapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates recommendation on Sernova Biotherapeutics Inc to Buy with a target price of CAD 1.60. Positive interim trial results for Cell Pouch Bio-hybrid Organ in type 1 diabetes patients

Buy Recommendation Research Update Target Price Clinical Trial Results Sernova Biotherapeutics Inc
BRIEF

published on 02/11/2025 at 13:41, 9 months 21 days ago

Sernova Biotherapeutics Gains Attention with Positive IND Application

Cell Pouch Sernova Biotherapeutics FDA IND Application Hypothyroidism Treatment Type 1 Diabetes Trial
PRESS RELEASE

published on 02/11/2025 at 13:36, 9 months 21 days ago

Original-Research: Sernova Biotherapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation for Sernova Biotherapeutics Inc. (ISIN: CA81732W1041) with a target price of CAD1.90. FDA IND application for Cell Pouch in hypothyroidism patients submitted

FDA First Berlin Equity Research Cell Pouch Sernova Biotherapeutics Inc Hypothyroidism
BRIEF

published on 09/27/2024 at 12:47, 1 year 2 months ago

Sernova Corp: First Berlin Equity Research Maintains Buy Rating

BUY Rating Sernova Corp Clinical Trial Type 1 Diabetes Cell Pouch
PRESS RELEASE

published on 09/27/2024 at 12:42, 1 year 2 months ago

Original-Research: Sernova Corp (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research reaffirms Buy rating for Sernova Corp (ISIN: CA81732W1041) with updated price target of CAD1.90 following positive results in treating type 1 diabetes

First Berlin Equity Research BUY Rating Sernova Corp Type 1 Diabetes CAD1.90
PRESS RELEASE

published on 02/06/2024 at 15:02, 1 year 9 months ago

Original-Research: Sernova Corp (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research has reiterated its BUY rating and CAD 3.80 price target for Sernova Corp (ISIN: CA81732W1041) based on the company's financial statement release and business update for FY 22/23. Sernova's achievements in diabetes treatment and potential partnering deal are anticipated to drive stock performance

First Berlin Equity Research Sernova Corp FY 22/23 Diabetes Treatment Partnering Deal
PRESS RELEASE

published on 10/19/2023 at 15:57, 2 years 1 month ago

Original-Research: Sernova Corp (von First Berlin Equity Research GmbH): BUY
PRESS RELEASE

published on 09/14/2023 at 22:06, 2 years 2 months ago

Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22
PRESS RELEASE

published on 09/13/2023 at 13:01, 2 years 2 months ago

Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update

Accesswire

Published on 12/05/2025 at 02:35, 10 hours 40 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 10 hours 45 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 12 hours 15 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 10 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 15 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 13:00, 15 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 15 minutes ago

Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 10 minutes ago

Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 15 minutes ago

CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 15 minutes ago

Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million

Les Echos

Published on 12/05/2025 at 08:45, 4 hours 30 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 15 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 19 hours 30 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 19 hours 31 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE